rethinkPeptides Search
Menu
Home / Research library
Study breakdown

GLP-1 drugs now being used for six conditions beyond diabetes including sleep apnea and liver disease

RPEP-135692025Sheth, Kyle; Kim, Stephanie; Porterfield, Laura; Virani, Salim S; Wadhwani, Shikha; Vaughan, Elizabeth M
evidence
The takeaway

GLP-1 receptor agonists have expanded from diabetes treatment to six additional applications: obesity, cardiovascular protection, kidney protection, obstructive sleep apnea, metabolic liver disease, and potentially substance use disorders.

6 uses beyond diabetes

GLP-1 drugs now have evidence supporting applications in obesity, heart, kidneys, sleep, liver, and addiction—transforming them into multi-system therapies

What the researchers found

Six applications beyond T2DM: obesity (strong evidence), cardiovascular protection (strong), kidney protection (strong), obstructive sleep apnea (emerging), MASLD (emerging), and substance use disorders (preliminary/variable). Cost and side effects limit access.

Why it matters

Understanding the full therapeutic scope of GLP-1 drugs helps clinicians maximize benefit for patients with multiple conditions, potentially treating several problems with one medication.

How the study worked

Narrative review of clinical evidence for GLP-1RA applications beyond diabetes.

What this study cannot tell us

Narrative review without systematic methodology. Evidence strength varies widely across the six indications. Cost and access barriers not quantified.

How to read the evidence

Narrative review. Evidence ranges from strong (obesity, CV) to preliminary (addiction). Provides useful overview but not systematic.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs are becoming the most versatile drug class in decades. Each new indication builds the case for broader prescribing and may justify addressing the cost barrier that limits access.

Questions still open

  • Which emerging indications will receive regulatory approval next?
  • How can GLP-1 drug costs be reduced to expand access?
  • Are the benefits consistent across different GLP-1 agonists?

Common questions

What can GLP-1 drugs treat besides diabetes?
Strong evidence supports their use for obesity and cardiovascular/kidney protection. Emerging evidence shows benefits for obstructive sleep apnea and fatty liver disease. Preliminary data suggest they may help with alcohol and nicotine addiction, though more research is needed.
Why are GLP-1 drugs called the most versatile new drug class?
Because they address multiple connected health problems simultaneously. A single medication can help with blood sugar, weight, heart protection, kidney protection, and potentially liver disease and addiction—conditions that frequently co-exist in the same patients.

Read the original research

The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes.

Current atherosclerosis reports, 27(1), 76

View on PubMed ↗Publisher’s paper ↗

Citation

Sheth, Kyle; Kim, Stephanie; Porterfield, Laura; Virani, Salim S; Wadhwani, Shikha; Vaughan, Elizabeth M. (2025). The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes.. Current atherosclerosis reports, 27(1), 76. https://doi.org/10.1007/s11883-025-01319-6